Company intelligence / Profile preview
Enzolytics, Inc.
Plano, Texas, United Statesenzolytics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Enzolytics has demonstrated clinical efficacy with its patented anti-HIV therapeutic ITV‑1 and continues to advance multiple preclinical programs using its proprietary fully human mAb technology against various infectious diseases. The company’s approach leverages AI to identify immutable viral targets and produce broadly neutralizing antibodies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Fully human monoclonal antibodies (mAbs)Proprietary proteins (e.g., Inactivated Pepsin Fraction/IPF)Immune therapeutics/vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Enzolytics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enzolytics, Inc..